Skip to main content
. Author manuscript; available in PMC: 2015 Nov 2.
Published in final edited form as: Dig Dis. 2013 Jan 3;30(0 3):112–118. doi: 10.1159/000342735

Table 2.

Potential factors influencing the use of methotrexate compared to other therapies in patients with IBD.

Positive Probably neither positive nor negative Negative
• Maintenance of remission in CD • Effective to induce remission (with steroids) in CD • Prior negative studies in UC
• Inexpensive • Toxicity (liver, lung, hematopoetic system) • Needs to be injected
• No increased lymphoma risk • Drug monitoring: No test to predict toxicity or therapeutic levels • Not to be used in case of anticipated pregnancy
• Fewer studies • Second/Third line recommendation (ECCO-guidelines)